Aldesleukin
- Generic Name
- Aldesleukin
- Brand Names
- Proleukin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 110942-02-4
- Unique Ingredient Identifier
- M89N0Q7EQR
- Background
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
- Indication
For treatment of adults with metastatic renal cell carcinoma.
- Associated Conditions
- Metastatic Melanoma, Metastatic Renal Cell Carcinoma ( mRCC)
- Associated Therapies
- -
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-08-03
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 332
- Registration Number
- NCT01174121
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 9
- Registration Number
- NCT01160445
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2012-10-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1
- Registration Number
- NCT00924001
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor
- Conditions
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2019-04-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5
- Registration Number
- NCT00923390
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 43
- Registration Number
- NCT00924326
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3
- Registration Number
- NCT00923806
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 4
- Registration Number
- NCT00923195
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
- First Posted Date
- 2008-05-02
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT00670748
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10
- Registration Number
- NCT00665470
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Evaluation of Clinical Efficacy and Immunologic Response After IL-2 Therapy in HCV-related Vasculitis Patients
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2013-01-24
- Target Recruit Count
- 10
- Registration Number
- NCT00574652
- Locations
- 🇫🇷
Hôpital de la Pitié, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.